Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure

Lancet

Volumn 349, Issue 9057, 1997, Pages 971-977

  Hampton, J R ^a   Van Veldhuisen, D J ^b   Kleber, F X ^c   Cowley, A J ^a   Ardia, A ^d   Block, P ^e   Cortina, A ^f   Cserhalmi, L ^g   Follath, F ^h   Jensen, G ⁱ   Kayanakis, J ^l   Lie, K I ^j   Mancia, G ^l   Skene, A M ^k  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Zambon Group SpA   (Italy)

^e Hôpital Universitaire des Enfants Reine Fabiola   (Belgium)

^f UNIVERSITY OF OVIEDO   (Spain)

^g Hungarian Institute of Cardiology   (Hungary)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k Nottingham Clinical Trial Data Centre   (United Kingdom)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; IBOPAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FATALITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL; SYMPTOM; VASODILATATION;

EID: 8244241095     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)10488-8     Document Type: Article

References (12)

1. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75.
2. Cowley AJ, Skene AM, on behalf of the Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Heart 1994; 72: 226-30.
3. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding fenequinan to patients wth congestive heart failure who remain asymptomatic on diuretics, digoxin and on angiotensin converting enzyme inhibitor? Circulation 1993; 88: 492-501.
4. Itoh H. Clinical pharmacology of ibopamine. Am J Med 1991; 90 (suppl 5B): 36S-42S.
5. Rousseau MF, Raigoso J, Van Eyll C, et al. Effects of intravenous epinine administration on left ventricular systolic performance: coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovas Pharmacol 1992; 19: 155-62.
6. van Veldhuisen DJ, Girbes ARJ, van den Broek SAJ, de Graeff PA, van Gilst WH, Lie KI. Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure. Am J Cardiol 1993; 71: 992-94.
7. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994; 73: 488-93.
8. van Veldhuisen DJ, Man in'T Veld AJM, Dunselman PHJM, et al. on behalf of the DIMT Study Group. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicentre Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-73.
9. Barabino A, Galbariggi G, Pizzorni C, Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991; 78: 243-56.
10. Dohmen HJM on behalf of the PRIME-I Study Group. Efficacy and safety of captopril and ibopamine in mild to moderate heart failure: results of the PRIME-I Study. Eur Heart J 1995; 16: 181 (abstr).
11. Hunt SM, McKenna SP. The Nottingham health profile user manual. Manchester: Galen Research, 1991.
12. van Veldhuisen DJ, Crijns HJ, Girbes ARJ, Tobe TJM, Wiesfeld ACP, Lie KI. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Am J Cardiol 1991; 68: 1194-202.